Aquestive Therapeutics Director Julie Krop Exercises and Sells 25,000 Shares

This SEC Form 4 filing reports that Julie Krop, a director of Aquestive Therapeutics, Inc. (AQST), executed a series of transactions on June 23, 2026. Krop exercised 25,000 non-qualified stock options at an exercise price of $0.7132 per share, acquiring 25,000 shares of common stock. Immediately following the exercise, she sold all 25,000 shares at $5.0157 per share. The transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan, which allows insiders to schedule trades in advance to avoid allegations of trading on non-public information. The stock options were originally granted on June 22, 2022 and were fully vested at the time of exercise. Following these transactions, Krop no longer holds any shares of Aquestive Therapeutics common stock. The filing was signed by Thomas Zalewski as Attorney-In-Fact on June 24, 2026.